| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 3 |
| 1 | CARBOPLATIN | 2 |
| 2 | TRAMETINIB | 2 |
| 3 | AGALSIDASE BETA | 1 |
| 4 | ATOVAQUONE | 1 |
| 5 | BISOPROLOL FUMARATE | 1 |
| 6 | DABIGATRAN ETEXILATE | 1 |
| 7 | DABIGATRAN ETEXILATE MESYLATE | 1 |
| 8 | DABRAFENIB | 1 |
| 9 | EVEROLIMUS | 1 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | INTERLEUKIN-12 HUMAN RECOMBINANT | 1 | 0.0909 |
| 1 | PALONOSETRON HYDROCHLORIDE | 1 | 0.0002 |
| 2 | ATOVAQUONE | 1 | 0.0001 |
| 3 | AGALSIDASE BETA | 1 | 0.0001 |
| 4 | TRAMETINIB | 2 | 0.0001 |
| 5 | EVEROLIMUS TABLETS | 1 | 0.0001 |
| 6 | DABRAFENIB | 1 | 0.0000 |
| 7 | TEMOZOLOMIDE | 1 | 0.0000 |
| 8 | BEVACIZUMAB | 3 | 0.0000 |
| 9 | EVEROLIMUS | 1 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC] | 1 | 0.0001 |
| 1 | Antimalarial [EPC] | 1 | 0.0001 |
| 2 | Antiprotozoal [EPC] | 1 | 0.0001 |
| 3 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 3 | 0.0000 |
| 4 | Platinum-based Drug [EPC] | 2 | 0.0000 |
| 5 | Alkylating Drug [EPC] | 1 | 0.0000 |
| 6 | Kinase Inhibitor [EPC] | 1 | 0.0000 |
| 7 | Proton Pump Inhibitor [EPC] | 1 | 0.0000 |